Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Trial Profile

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs TG 1701 (Primary) ; Ublituximab; Umbralisib
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 13 Nov 2018 According to a TG Therapeutics Inc media release, the first cohort evaluating TG-1701 at a dose of 100 mg once-daily has been fully enrolled.
    • 12 Sep 2018 Status changed from planning to recruiting.
    • 21 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top